Lupin launches dapagliflozin tablets 5 & 10 mg in US after FDA approval

Lupin stated that the product is bioequivalent to Farxiga for the indications specified in the approved labelling. Shares of Lupin Ltd ended at ₹2,332.80, up by ₹36.65, or 1.60%, on the BSE.

Leave a Reply

Your email address will not be published. Required fields are marked *